Status:
UNKNOWN
Intradermal Needle Therapy for Major Depressive Disorder
Lead Sponsor:
The Third Affiliated hospital of Zhejiang Chinese Medical University
Collaborating Sponsors:
The Zhejiang Provincial Tongde Hospital
The Affiliated Hangzhou First People's Hospital
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
12-60 years
Phase:
NA
Brief Summary
Major depressive disorder (MDD) is a common mental disorder that affects patients' physical health and quality of life. Although traditional acupuncture therapy has certain advantages in improving MDD...
Detailed Description
A total of 120 participants with MDD who meet the inclusion criteria will be included in the study. Participants will be randomly divided into the SSRIs + acupuncture group, acupuncture + placebo grou...
Eligibility Criteria
Inclusion
- 1\. Patients should meet the diagnostic criteria of the International Classification of Diseases 10th Edition (ICD-10) diagnostic criteria for depression and are evaluated as moderate or severe MDD according to the severity of depression; 2. 12 ≤ age ≤60, male or female; 3. Participants have clear consciousness and could communicate with others normally; 4. Participants could understand the full study protocol and have high adherence. Written informed consent is signed by themselves or their lineal kin (for minor participants, their guardian should sign the informed consent form for them).
Exclusion
- 1\. Participants with serious primary diseases of cardiovascular, respiratory, digestive, urinary, hematological, endocrine, neurological disease, and other serious primary diseases, and the disease cannot be effectively controlled clinically; 2. Major depressive disorders caused by organic mental disorders, schizophrenia, bipolar disorder, psychoactive substances, and non-addictive substances; 3. Participants with suicidal tendencies; 4. Pregnant or lactating participants; 5. Participants taking other antidepressants that were not SSRIs or the pharmacological effects of such antidepressants have not been cleared; 6. Participants with intellectual disabilities who cannot cooperate with the questionnaire survey; 7. Participants with bleeding tendency, skin disease, allergic constitution, and allergic to adhesive tape; 8. Participants are participating in other trials.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05352113
Start Date
May 1 2022
End Date
December 30 2025
Last Update
April 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiaomei Medical Shao
Hangzhou, Zhejiang, China